Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 9/20 | 0.53 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | HTR1B | P28222 | 1/20 | 0.31 |
| ▸ | HTR1F | P30939 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26419367 | 1.00 | AHR (0.53) | AHRPTGDR2LMNAMAPTNLRP3 | |
| SCHEMBL26419372 | 1.00 | AHR (0.53) | AHRPTGDR2LMNAMAPTNLRP3 | |
| SCHEMBL26089047 | 0.86 | AHR (0.70) | AHRPTGDR2LMNAMAPTNLRP3 | |
| SCHEMBL26086751 | 0.86 | AHR (0.70) | AHRPTGDR2LMNAMAPTNLRP3 | |
| SCHEMBL26087025 | 0.86 | AHR (0.70) | AHRPTGDR2LMNAMAPTNLRP3 | |
| SCHEMBL26419139 | 0.84 | AHR (0.54) | AHRLMNAMAPTNLRP3HTR1A | |
| SCHEMBL26419127 | 0.84 | AHR (0.54) | AHRLMNAMAPTNLRP3HTR1A | |
| SCHEMBL26086929 | 0.84 | AHR (0.54) | AHRLMNAMAPTNLRP3HTR1A | |
| SCHEMBL27266394 | 0.81 | AHR (0.34) | AHRPTGDR2 | |
| SCHEMBL27266390 | 0.81 | AHR (0.34) | AHRPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037322-B2 | AHR agonists | ELI LILLY AND COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-20230127797-A1 | AHR AGONISTS | ELI LILLY AND COMPANY | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037322-B2 | AHR agonists | AHR, ARNT, RORC | AHR 1/4885PTGDR2 524/4885LMNA 4176/4885 |
| US-20230127797-A1 | AHR AGONISTS | AHR, ARNT, RORC | AHR 1/4885PTGDR2 524/4885LMNA 4176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.